Form 483 Observations Are Not GMP Guidance, FDA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Industry should not use observations from FDA-483 reports as good manufacturing practices guidance, CDER Office of Compliance Director David Horowitz said.
You may also be interested in...
FDA Good Manufacturing Practices Initiative Report Slated For October
GMP initiative report will include final guidance on process analytical technologies and aseptic processing, as well as draft guidance on the use of quality systems and computerized systems in clinical trials. The release will also contain "white paper" on prioritizing manufacturing sites for inspections.
Lupus Guidance Suggests Broad Use Of Health-Related Quality Of Life Endpoint
FDA’s draft guidance on systemic lupus erythematosus drug development lists four possible claims that the agency “may be willing to approve”: reduction in disease activity; organ-specific lupus treatment; complete clinical response/remission; and reduction in flares.
RiskMAP Guidance Includes Plans For A Website
FDA is planning to develop a Risk Minimization Action Plan website, an agency risk management guidance states